Hengrui Pharmaceuticals Gets NMPA Green Light for SHR-A2009 Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration...
PD-1/L1
Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug...
Summit Therapeutics and Pfizer Collaborate on Ivonescimab-ADC Combo for Solid Tumors
Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for...
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...
Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National...
Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co.,...
Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study
Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from...
Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...
Sunshine Guojian and Shenyang 3SBio License 612 and 708 Programs for Anti-Tumor Development
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd and Shenyang 3SBio Co., Ltd, both subsidiaries of...
Zelgen Biopharmaceuticals’ ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...
Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...
Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study
US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study...
Henlius Biotech Doses First Patient in HLX43 Phase II Study for Esophageal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a Phase II...
Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...
NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer
The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...
Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs
Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues...
Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Akeso Biopharma Receives Development Payment for PD-L1 Monoclonal Antibody
China-based Akeso Biopharma (HKG: 9926) has announced receiving a drug collaboration development payment from compatriot...
GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU
UK-based GSK plc (NYSE: GSK, LON: GSK) has announced receiving approval from the European Commission...
Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving another clearance from the...